Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-292
2023-504997-39-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of capivasertib in breast cancer (2 arms), sponsored by AstraZeneca. Planned start Jun 2021; status: authorised.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-504997-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504997-39-00.